# Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

> **NCT01499095** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 811 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Lantus (Insulin glargine)
- **DRUG:** HOE901-U300 (new formulation of insulin glargine)

## Key facts

- **NCT ID:** NCT01499095
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-11
- **Target enrollment:** 811 (ACTUAL)
- **Last updated:** 2022-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01499095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01499095, "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01499095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*